On July 1, Hengrui Pharmaceutical announced that the drug HR17031 injection has obtained the clinical trial qualification of the US FDA and is intended to be used for the treatment of type 2 diabetes
.
At present, two similar drugs have been approved by the FDA and the European Medicines Agency for the treatment of type 2 diabetes, namely Novo Nordisk’s Xultophy 100/3.
and Sanofi’s Soliqua 100/33
.
After querying the EvaluatePharma database, the global sales of Xultophy 100/3.
6 in 2020 will be approximately 374 million U.
S.
dollars, and the global sales of Soliqua 100/33 will be approximately 184 million U.
S.
dollars
.
Up to now, Hengrui has invested approximately RMB 113.
71 million in research and development expenses in HR17031-related projects
.
